Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Degarelix (Primary) ; Enzalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 30 Apr 2025 Results assessing acute effects of AR inhibition in hormone-sensitive mPC to identify therapeutic targets to prevent resistance, presented at the 116th Annual Meeting of the American Association for Cancer Research.
- 06 Oct 2020 Results evaluating prostate multiparametric MRI (mpMRI) before and after neoadjuvant enzalutamide plus ADT, published in the Clinical Cancer Research
- 24 Jun 2020 Results assessing morphologic effects of treatment with neoadjuvant enzalutamide and androgen deprivation therapy in high risk prostatic cancer, presented at the 111th Annual Meeting of the American Association for Cancer Research - II